SLS Management’s Myriad Genetics MYGN Stock Holding History

SLS Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-109,300	Closed	-$3.35M	–	14
2016 Q2	$3.35M	Buy	+109,300	New	+$3.8M	7.34%	4

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

SLS Management's MYGN Position: Q3 2016 in Review

SLS Management sold out of Myriad Genetics (MYGN) in Q3 2016, closing a stake of 109,300 shares — an estimated $3.35M sold.

SLS Management first reported a position in MYGN in Q2 2016 and held it in 1 quarter. The position peaked at $3.35M in Q2 2016. 223 funds tracked by Wall St. Rank hold MYGN as of Q3 2016.

SLS Management reported no remaining Myriad Genetics position as of Q3 2016 after selling out during the quarter.
SLS Management sold 109,300 Myriad Genetics shares in Q3 2016, an estimated $3.35M.
SLS Management first reported a position in Myriad Genetics in Q2 2016 and held it in 1 quarter.
SLS Management's Myriad Genetics position peaked at $3.35M in Q2 2016.
223 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2016.

Based on SLS Management's 13F filing for Q3 2016, filed 14 Nov 2016.